OSR Holdings, Inc. is a global healthcare company, dedicated to advancing healthcare outcomes and improving the quality of life for people and their families. The Company is focused on building and developing a portfolio of transformative therapies and healthcare solutions. The Company's operating businesses (through its three wholly owned subsidiaries) include developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases and neurovascular intervention medical device and systems distribution in Korea. The Company’s subsidiary, Vaximm’s flagship asset, VXM01, is a late clinical-stage (NCT037500701) immuno-oncology candidate for glioblastoma. Vaximm has three clinical and pre-clinical drug candidates targeting diseases ranging from glioblastoma to gastrointestinal stromal tumor to ocular diseases. The Company has operations in Europe and South Korea.
Símbolo de cotizaciónOSRH
Nombre de la empresaOSR Holdings Inc
Fecha de salida a bolsaFeb 10, 2023
Director ejecutivoHwang (Kuk Hyoun)
Número de empleados- -
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 10
Dirección10900 Ne 4Th Street, Suite 2300
CiudadBELLEVUE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal98004
Teléfono14256357700
Sitio Webhttps://osr-holdings.com/
Símbolo de cotizaciónOSRH
Fecha de salida a bolsaFeb 10, 2023
Director ejecutivoHwang (Kuk Hyoun)
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos